盐酸莫西沙星氯化钠注射液致中毒性表皮坏死松解症1例分析

doi:10.19803/j.1672-8629.20241028

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (11): 1307-1309.
DOI: 10.19803/j.1672-8629.20241028

盐酸莫西沙星氯化钠注射液致中毒性表皮坏死松解症1例分析

司福国¹, 崔佳^1*, 程军¹, 朱裕林², 戴彪³

¹安徽省蚌埠市第三人民医院药学部,安徽蚌埠 233000;
²蚌埠医科大学第一附属医院药剂科,安徽蚌埠 233000;
³安徽省合肥第四人民医院药剂科,安徽合肥 230022

收稿日期:2024-12-24 出版日期:2025-11-15 发布日期:2025-11-14
通讯作者: ^*崔佳,女,硕士,副主任药师,临床药学。E-mail: 114087729@qq.com
作者简介:司福国,男,本科,副主任药师,临床药学。
基金资助:
安徽省卫生健康委员会项目（AHWJ2024Ab0143）

One Case of Toxic Epidermal Necrolysis Caused by Moxifloxacin Hydrochloride and Sodium Chloride Injection

SI Fuguo¹, CUI Jia^1*, CHENG Jun¹, ZHU Yulin², DAI Biao³

¹Department of Pharmaceutical Affairs, the Third People's Hospital of Bengbu, Bengbu Anhui 233000, China;
²Department of Pharmacy,the First Affiliated Hospital of Bengbu Medical University,Bengbu Anhui 233000, China;
³Department of Pharmacy, Hefei Fourth People's Hospital, Hefei Anhui 230022, China

Received:2024-12-24 Online:2025-11-15 Published:2025-11-14

摘要/Abstract

摘要： 目的探究盐酸莫西沙星氯化钠注射液致中毒性表皮坏死松解症（TEN）病例,为临床合理用药提供参考。方法梳理1例肺鳞癌成人患者应用盐酸莫西沙星氯化钠注射液发生TEN的案例,对致敏药物进行筛选,并分析其发生机制及危险因素。结果根据患者临床表现,结合其用药史,通过诺氏量表评分、表皮坏死松解症药物因果关系推算法(ALDEN)和致敏机制分析,确定TEN的致敏药物为盐酸莫西沙星氯化钠注射液,经过积极治疗,患者逐渐康复。盐酸莫西沙星氯化钠注射液致TEN的其发生机制尚未明确,危险因素为低蛋白血症与β-内酰胺类药物过敏史。结论临床应用盐酸莫西沙星氯化钠注射液应警惕发生TEN的风险,建议加强不良反应监测,尤其是有过敏史的患者,以保障患者用药安全。

关键词: 盐酸莫西沙星氯化钠, 注射液, 中毒性表皮坏死松解症, 低蛋白血症, 肺鳞癌, 表皮坏死松解症药物因果关系推算法标准, 药品不良反应

Abstract: Objective To analyze one case of toxic epidermal necrolysis (TEN) caused by moxifloxacin hydrochloride and sodium chloride injection in order to provide a reference for rational drug use in clinic. Methods One case of TEN caused by moxifloxacin hydrochloride and sodium chloride injection in an adult patient with lung squamous cell carcinoma was analyzed, the sensitizing drug was identified, and the causes and risk factors were analyzed. Results According to clinical symptoms and medication of the patient, moxifloxacin hydrochloride and sodium chloride injection was identified as the sensitizing drug of TEN via the Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN) standards. Effective treatment was offered and the patient was gradually improved. The pathogenesis of TEN linked to moxifloxacin hydrochloride and sodium chloride injection remained unclear, and risk factors were hypoproteinemia and hypersensitivity reactions to β-lactam antibiotics. Conclusion Clinicians who prescribe moxifloxacin hydrochloride and sodium chloride injection should be alert to the risk of TEN, monitor adverse reactions, especially among patients with a history of allergy, and ensure safety in clinical practice.

Key words: Moxifloxacin Hydrochloride and Sodium Chloride, Injection, Toxic Epidermal Necrolysis, Hypoproteinemia, Lung Squamous Cell Carcinoma, ALDEN, Adverse Drug Reactions

中图分类号:

司福国, 崔佳, 程军, 朱裕林, 戴彪. 盐酸莫西沙星氯化钠注射液致中毒性表皮坏死松解症1例分析[J]. 中国药物警戒, 2025, 22(11): 1307-1309.

SI Fuguo, CUI Jia, CHENG Jun, ZHU Yulin, DAI Biao. One Case of Toxic Epidermal Necrolysis Caused by Moxifloxacin Hydrochloride and Sodium Chloride Injection[J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1307-1309.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20241028

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I11/1307

参考文献

[1] HE XY, LIU JQ, CHEN R, et al.A Retrospective Analysis of Nursing Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis[J]. J Diagn Ther Dermato-Venereol(皮肤性病诊疗学杂志), 2024, 31(8): 546-550.
[2] THONG BY.Drug-Induced Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Interpreting the Systematic Reviews on Immunomodulatory Therapies[J]. Asia Pac Allergy, 2023, 13(2): 72-76.
[3] NORI S, NEBESIO C, BRASHEAR R, et al.Moxifloxacin-Associated Drug Hypersensitivity Syndrome with Toxic Epidermal Necrolysis and Fulminant Hepatic Failure[J]. Arch Dermatol, 2004, 140(12): 1537-1538.
[4] BAI H, TONG WW, WEI XQ, et al.Analysis of a Case of Death with Severe Acute Pancreatitis and Toxic Epidermal Necrolysis[J]. Chin Hosp Pharm J(中国医院药学杂志), 2015, 35(8): 763-764.
[5] ZHANG YP, ZHENG XY, WU JH.Identification of Sensitizing Drugs in a Case of Toxic Epidermal Necrolysis by ALDEN Standard[J]. Chin J Phamiacoepidemiol(药物流行病学杂志), 2021, 30(9): 626-630.
[6] HOWARD-THOMPSON A, CARTMELL B, SUDA KJ.Toxic Epidermal Necrolysis Reaction Associated with the Use of Moxifloxacin[J]. Int J Antimicrob Agents, 2014, 44(2): 178-179.
[7] WANG Y, GUO Q, LI Z, et al.Toxic Epidermal Necrolysis Induced by Moxifloxacin and Exacerbated by Clindamycin in an Elderly Patient: a Case Report[J]. Front Med (Lausanne), 2025, 12: 1527051.
[8] SHI JF, JIANG L.Literature Analysis of Serious Immune-Related Adverse Events Caused by Tislelizumab in Patients[J]. Anti-Infection Pharmacy(抗感染药学), 2023, 20(8): 805-809.
[9] XIE JQ, MA XW, WANG HX.Correlation Analysis of Flurbiprofen Axetil and Hypoxemia Coma Based on Naranjo's Assessment Scale[J]. China Pharmaceuticals(中国药业), 2023, 32(2): 117-119.
[10] YANG W, LU Y, WU Z, et al.Toxic Epidermal Necrosis Associated with Afatinib: a Case Report and Literature Review[J]. Front Oncol, 2023, 12: 1010052.
[11] DODIUK-GAD RP, CHUNG WH, VALEYRIE-ALLANORE L, et al.Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: an Update[J]. Am J Clin Dermatol, 2015, 16(6): 475-493.
[12] DHAVALESHWAR A, NAYAK V, HANDE M, et al.Topical Moxifloxacin-Induced Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome[J]. J Postgrad Med, 2019, 65(2): 125-126.
[13] Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert Consensus on the Diagnosis and Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis[J]. Chin J Dermatol(中华皮肤科杂志), 2021, 54(5): 376-381.
[14] LEE EY, KNOX C, PHILLIPS EJ.Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a Systematic Review and Meta-Analysis[J]. JAMA Dermatol, 2023, 159(4): 384-392.
[15] AQUET P, JACOB E, DAMAS P, et al.Recurrent Fatal Drug-Induced Toxic Epidermal Necrolysis (Lyell's Syndrome) after Putative Beta-Lactam Cross-Reactivity: Case Report and Scrutiny of Antibiotic Imputability[J]. Crit Care Med, 2002, 30(11): 2580-2583.
[16] ULLDEMOLINS M, ROBERTS JA, RELLO J, et al.The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients[J]. Clin Pharmacokinet, 2011, 50(2): 99-110.
[17] YAN YH, WANG JQ, ZHOU CH.Overview of Research on the Analysis Methods for Free Drug Concentration in Plasma[J]. Journal of Hebei Medical University(河北医科大学学报), 2025, 46(3): 366-373.
[18] KUULA LSM, BACKMAN JT, BLOM ML.Healthcare Costs and Mortality Associated with Serious Fluoroquinolone-Related Adverse Reactions[J]. Pharmacol Res Perspect, 2022, 10(2): E00931.

盐酸莫西沙星氯化钠注射液致中毒性表皮坏死松解症1例分析

One Case of Toxic Epidermal Necrolysis Caused by Moxifloxacin Hydrochloride and Sodium Chloride Injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	蒋晓峰, 杨淑婷, 白丽琴, 戚俊, 何建雄, 陈文戈, 梁祖红, 李渔, 余晓霞. 医疗机构制剂不良反应监测与评价系统构建及初步实践[J]. 中国药物警戒, 2025, 22(9): 1008-1011.
[2]	蔡杰, 韩陈媛, 江君微. 887例静脉滴注抗菌药物不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1018-1023.
[3]	郑金凤, 吴佳妮, 林京玉, 杨雪卿. 222例口服凝血因子Xa抑制剂不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1024-1028.
[4]	谢加力, 荀艳, 陶云松, 章圣朋. 211例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1029-1033.
[5]	刘芹, 章嘉一, 吴烜, SOANES Nigel. 基于生成式人工智能大语言模型的文献来源药品不良反应报告自动生成平台研究与应用[J]. 中国药物警戒, 2025, 22(9): 1040-1044.
[6]	李舒悦, 邱慧颖, 吴佳琪, 高君伟. 炔雌醇环丙孕酮片致急性髓系白血病患者血小板减少期间血栓形成2例分析[J]. 中国药物警戒, 2025, 22(9): 1045-1048.
[7]	李丹, 阳雄文, 陈丹君, 付成效, 阳波. 苯扎贝特片致慢性肾病患者横纹肌溶解1例分析[J]. 中国药物警戒, 2025, 22(9): 1049-1050.
[8]	钱凤丹, 张立超, 贡翊斐. 注射用尖吻蝮蛇血凝酶致严重过敏性休克1例分析[J]. 中国药物警戒, 2025, 22(9): 1051-1053.
[9]	邵一帆, 陈秋岑, 翟惠奇, 吴伟, 褚庆民. 铝碳酸镁咀嚼片致严重过敏反应1例分析[J]. 中国药物警戒, 2025, 22(9): 1054-1056.
[10]	魏盈, 李文凤, 张宇飞, 侯欣, 杨彦伟, 樊永丽. 度伐利尤单抗注射液致脓疱型银屑病1例分析[J]. 中国药物警戒, 2025, 22(9): 1057-1060.
[11]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[12]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[13]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[14]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[15]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.